secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001558370-25-006739
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q1 2025 revenue down 8% to $10.4M; reiterates FY2025 guidance
---------------------------------------------------------------------

- Total revenue $10.4M (-8% YoY); core revenue $8.2M (+1%); SPL program revenue $2.1M (-32%).
- Net loss $10.3M vs $9.5M in Q1 2024; cash $174.7M as of March 31, 2025.
- Added one SPL client (TG Therapeutics); total active SPLs now 29.
- Reiterates FY2025: core revenue growth 8-15%, SPL program revenue ~$5M, ending cash ~$160M.
- Integration of SeQure Dx ongoing; management cites robust SPL pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025006739/0001558370-25-006739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000155837025006739/mxct-20250507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer